Connect Biopharma announces results from rademikibart study

Connect Biopharma (CNTB) announced results from a Phase 3 52-week study in patients with moderate-to-severe atopic dermatitis conducted by the company’s partner in China, Simcere Pharmaceutical, which were presented during the late-breaking research session of the 2026 American Academy of Dermatology annual meeting on March 28 in Denver, Colorado. The 52-week Phase 3 study was a double-blind, placebo-controlled trial in China that enrolled 259 adolescent and adult patients with moderate-to-severe AD, who were randomized to receive rademikibart 300 mg administered every two weeks or placebo via SC injection during a 16-week induction phase, followed by a 36-week maintenance phase in which patients randomized to rademikibart continued on rademikibart and patients randomized to placebo switched to rademikibart. At Week 52, rademikibart demonstrated strong maintenance of response among Week 16 responders, with continued improvement across all key efficacy endpoints. Rademikibart demonstrated: 96.6% of patients achieved a 75% reduction from baseline in the Eczema Area and Severity Index; 87.1% of patients achieved a score of 0 or 1 with at least a 2-point reduction on the Investigator’s Global Assessment of Atopic Dermatitis and 85.3% of patients achieved a 90% reduction from baseline in the Eczema Area and Severity Index. Rademikibart was well tolerated with safety similar to placebo at 16 weeks and lower conjunctivitis than other agents in the class. No significant, drug-related safety issues observed in over 1,500 participants receiving rademikibart in completed studies across indications.